Friday, 23 Mar 2018

You are here

US Drug Spending Will Rise Steadily Thru 2021

Reuters has reported that U.S.spending on prescription drugs in 2016 increased by 5.8 percent over 2015 levels to $450 billion based on list prices, and by 4.8 percent to $323 billion when adjusted for discounts and rebates.

A forecast from Quintiles/IMS indicates that the cost of prescription medicines in the United States will increase 4-7 percent through 2021, reaching nearly $600 billion.

QuintilesIMS (previously known as IMS) compiles data for the pharmaceutical industry, has reduced its projections due to fewer new medicines being approved in 2016.

Taking likely manufacturer discounts and rebates into account, spending would grow 2-5 percent to $375 billion to $405 billion in 2021, as net price increases for patent-protected branded drugs slows, the report said.

The rising cost of drugs is becoming a major issue with politicians and insurers, for both generic and branded medicines.

The number of new drug approvals by the FDA has declined to 22 new medicines in 2016, which is down from 45 in 2015, 

The projected estimates taking into account that new drug approvals will rebound in 2019 and after, as QuintilesIMS estimates 40 to 45 new brand launches per year through 2021.


Spending on pain medicines declined 1 percent, while prescription growth was seen with chronic therapies, such as those for hypertension and mental health.


The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Shoe Inserts Disappoint with Plantar Heel Pain

A report from the British Journal of Sports Medicine shows that commonly used drug store shoe inserts or customized orthotics are often ineffective in managing plantar heel pain.

Leflunomide May Sensitize the Insulin Receptor and Have an Anti-Glycemic Effect

An animal model study in the Journal of Endocrinololgy reports the potential use of leflunomide in the control of hyperglycemia in male mice. 

2017 Rheumatology Year in Review

This retrospective review is drawn from the authors collection of the most impactful publications, research and news that occurred in 2017.  In no particular order, here are my top rheumatology advances, news and research reports for calendar year 2017.

Oral Anticoagulation Effective Following Hip and Knee Replacement Surgery

Many protocols call for anticoagulation after total hip or total knee arthroplasty to prevent venous thromboembolism (proximal deep-vein thrombosis or pulmonary embolism), and some reports have suggested a role for aspiring or direct oral anticoagulants as preventative therapy. The NEJM has reported that oral anticoagulation with rivaroxaban (Xarelto) followed by aspirin to be effective prophylaxis.

Calcium and Vitamin D Do Not Increase Cardiac Events/Death

An analysis of the UK Biobank study found no link between calcium/vitamin D supplementation and incident cardiovascular events/deaths in a large prospective study of 475,255 men and women aged 40 to 69 years.

Results published in Journal of Bone and Mineral Research used registry data to identify coded incident hospital admissions for ischemic heart disease (IHD), myocardial infarction (MI), and subsequent death.